Olaparib tablets safe in patients with relapsed ovarian cancer
the ONA take:
According to new results presented at the Marsha Rivkin Center for Ovarian Cancer Research - American Association for Cancer Research (AACR) 10th Biennial Ovarian Cancer Research Symposium, olaparib, in oral tablet form rather than capsule form, administered in combination carboplatin and paclitaxel was found to be safe for the treatment of patients with relapsed ovarian cancer.
In the phase 1b clinical study, researchers enrolled 14 patients between ages 42 and 77 with relapsed ovarian cancer. Patients received carboplatin and paclitaxel once weekly for 3 weeks of a 28-day cycle in combination with escalated doses of olaparib. Researchers found the maximum tolerable dose of olaparib to be 150 mg two times per day for 3 consecutive days weekly of each cycle.
Of 12 patients able to be evaluated, four experienced a complete response, four had a partial response, two had stable disease, and two experienced disease progression. In regard to safety, bone marrow suppression was the most common grade 3 toxicity, as expected with carboplatin and paclitaxel.
The study results also suggest that those patients with BRCA mutations detected in their tumors may have responded better compared with those who did not have a mutation. Researchers plan to initiate a phase 2 extension study.
Olaparib with carboplatin and paclitaxel safe for ovarian cancer.
An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to phase Ib clinical trial data presented at the Marsha Rivkin Center for Ovarian Cancer Research-AACR 10th Biennial Ovarian Cancer Research Symposium.
"This study is one of the first studies to use olaparib tablets instead of olaparib capsules," said Saul Rivkin, MD, founder and chairman of the Marsha Rivkin Center for Ovarian Cancer Research, and a research scientist at the Swedish Cancer Institute, both in Seattle, Washington.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|